NewAmsterdam Pharma Company N.V./$NAMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Ticker
$NAMS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
77
ISIN
NL00150012L7
Website
NAMS Metrics
BasicAdvanced
$2.1B
-
-$1.85
0.01
-
Price and volume
Market cap
$2.1B
Beta
0.01
52-week high
$26.95
52-week low
$14.06
Average daily volume
625K
Financial strength
Current ratio
19.977
Quick ratio
19.761
Long term debt to equity
0.018
Total debt to equity
0.05
Management effectiveness
Return on assets (TTM)
-18.15%
Return on equity (TTM)
-31.51%
Valuation
Price to revenue (TTM)
40.677
Price to book
2.73
Price to tangible book (TTM)
2.73
Price to free cash flow (TTM)
-13.625
Growth
Revenue change (TTM)
586.97%
Earnings per share change (TTM)
-32.18%
3-year revenue growth (CAGR)
-2.29%
3-year earnings per share growth (CAGR)
110.07%
NAMS News
AllArticlesVideos
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
GlobeNewsWire·1 week ago
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
GlobeNewsWire·4 weeks ago
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NewAmsterdam Pharma Company N.V. stock?
NewAmsterdam Pharma Company N.V. (NAMS) has a market cap of $2.1B as of June 04, 2025.
What is the P/E ratio for NewAmsterdam Pharma Company N.V. stock?
The price to earnings (P/E) ratio for NewAmsterdam Pharma Company N.V. (NAMS) stock is 0 as of June 04, 2025.
Does NewAmsterdam Pharma Company N.V. stock pay dividends?
No, NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders as of June 04, 2025.
When is the next NewAmsterdam Pharma Company N.V. dividend payment date?
NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders.
What is the beta indicator for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. (NAMS) has a beta rating of 0.01. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.